SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is experiencing significant volatility and upward momentum driven by intense short-squeeze dynamics, with investors closely watching a recent SEC filing regarding executive change-of-control agreements as a potential precursor to a buyout. The community is heavily focused on the scarcity of available shares, high borrow rates, and the anticipation of topline results from the Phase 3 REGAL trial for their lead AML immunotherapy.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is attracting significant attention as investors anticipate a potential inclusion in the Russell 1000, which many hope will trigger forced buying and fuel a major short squeeze against the heavily shorted float. The community remains focused on upcoming catalysts, including potential label expansions, global commercialization progress in regions like Saudi Arabia, and the company's advancements in NK cell manufacturing technology.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors react to a significant CFO leadership transition and the disclosure of a one-time tariff refund set to boost upcoming financial results. The community remains deeply divided, with many debating if this news marks a fundamental turnaround for the iconic brand or if the stock remains a value trap ahead of its earnings report.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors monitor the aftermath of a federal appeals court decision that affirmed the dismissal of its lawsuit against CMS, shifting focus toward the company's long-term commercial execution and revenue growth. The community remains actively focused on the potential for sustained profitability and the long-term strategic path for its flagship products as management pivots to private insurers.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as investors react to a new $6 billion share repurchase program, signaling management's confidence despite ongoing cyclical pressures in automotive and industrial markets. The community remains focused on the stock's potential for a long-term rebound, closely monitoring its performance as it navigates support levels and potential technical breakouts.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending following news that the FDA has scheduled an advisory committee meeting for its DMD therapy, a development that triggered short-term volatility as traders de-risked ahead of the upcoming decision date. Despite the market's reaction, the community remains heavily focused on the company's strong five-year clinical data, viewing the meeting as a potential opportunity to secure a broader product label rather than a sign of rejection.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors weigh recent strategic investments in U.S.-based photonic chip manufacturing against technical selling pressure. While the community is actively debating the stock's transition from a legacy telecom player to an AI-native infrastructure provider, sentiment is split between those viewing the current price as an accumulation opportunity and traders frustrated by near-term volatility and option-related suppression.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is seeing high volatility as retail investors chase momentum in the memory and storage sector, leading to intense debates between bulls betting on sustained AI-driven demand and bears warning of a potential bubble. The stock is currently oscillating amidst significant short-term swings, with the community closely tracking price action in peers like Micron and SanDisk for broader sector sentiment.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending due to a significant earnings beat and raised full-year revenue guidance that has fueled investor optimism around its QNX software and Physical AI growth potential. Community sentiment is overwhelmingly bullish, with many investors highlighting key partnerships and the upcoming Alloy Kore platform as catalysts for a potential long-term rerating, while actively calling out short-sellers and underestimating analyst targets.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as retail investors engage in a heated debate over the company's lack of upward price momentum and delayed relisting plans despite aggressive store expansion and strong operational metrics. The community is actively tracking potential corporate maneuvers, including strategic buybacks and international growth efforts, while speculating on the timing of a return to major exchanges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the...

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.

Glaukos Announces Participation in Upcoming Investor Conferences

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today...

Insider Selling: Glaukos (NYSE:GKOS) COO Sells 19,573 Shares of Stock

Glaukos Corporation (NYSE:GKOS - Get Free Report) COO Joseph Gilliam sold 19,573 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $143.54, for a total transaction of $2,809,508.42. Following the completion of the sale, the chief operating officer...

Alex Thurman Sells 10,000 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 10,000 shares of Glaukos stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $140.00, for a total value of $1,400,000.00. Following the completion of the transaction, the chief financial...

Leana Wen Sells 1,700 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Leana Wen sold 1,700 shares of the stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total transaction of $243,695.00. Following the sale, the director directly owned 19,739...

Vanguard Group Inc. Sells 26,028 Shares of Glaukos Corporation $GKOS

Vanguard Group Inc. decreased its holdings in Glaukos Corporation (NYSE:GKOS - Free Report) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,020,492 shares of the medical instruments supplier's sto...

UBS Group AG Increases Position in Glaukos Corporation $GKOS

UBS Group AG raised its holdings in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 316.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 873,942 shares of the medical instruments supplier's stock after b...

Glaukos (NYSE:GKOS) Stock Rating Upgraded by Wall Street Zen

Wall Street Zen upgraded shares of Glaukos from a "hold" rating to a "buy" rating in a research note on Saturday...

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Glaukos (NYSE:GKOS) Stock

JPMorgan Chase & Co. increased their price target on Glaukos from $120.00 to $140.00 and gave the stock an "overweight" rating in a report on Thursday...

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard A. Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Glaukos Corporation

Why Glaukos Stock Jumped Over 20% After-Hours Today

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.21	--	--	N/A
Q1 '26	-$0.28	-$0.18	35.87%	BEAT
Q4 '25	-$0.20	-$0.28	-43.08%	MISSED
Q3 '25	-$0.26	-$0.16	38.60%	BEAT
Q2 '25	-$0.26	-$0.24	9.16%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

GKOSGlaukos Corporation

Upcoming Earnings: Q2 '26

Historical Earnings

Latest GKOS News